Proton pump inhibitor therapy: Preliminary results of a therapeutic interchange program

American Journal of Managed Care

Volumn 6, Issue 5, 2000, Pages 593-601

  Amidon, Phillip B ^a   Jankovich, Rhonda ^a   Stoukides, Cheryl A ^b,c   Kaul, Alan F ^b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Medical Outcomes Management Inc   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; FAMOTIDINE; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; COST OF ILLNESS; DIARRHEA; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; DRUG COSTS; HUMANS; MEDICAL AUDIT; MIDDLE AGED; OMEPRAZOLE; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIC ULCER; PROTON PUMPS; RETROSPECTIVE STUDIES;

EID: 0034063629     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. VA implements national drug formulary. Available at: http://www.hcst.net/afsa751/int/f5970616.htm. Accessed January 19, 2000.
2. Chon HS, Suzuki NT. Evaluation of omeprazole to lansoprazole conversion in a VA Medical Center. Paper presented at: ASHP Midyear Clinical Meeting; December 6-10, 1998; Las Vegas, NV. Abstract 33Dec:P-122E.
3. Spencer JA. Antisecretory utilization at a Veterans' Administration hospital: 6-month DUR. Paper presented at: ASHP Midyear Clinical Meeting; December 6-10, 1998; Las Vegas, NV. Abstract 33Dec:P-121E.
4. Condra LJ, Morreale AP, Stolley SN, Marcus D. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. Pharmacotherapy 1999;19(4):498. Abstract 133.
5. Condra LJ, Morreale AP, Stolley SN, Marcus D. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. Am J Manag Care 1999;5:631-638.
6. Morreale AP, Condra LJ, Stolley SN. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. Gastroenterology 1999;116(4 pt 2):G1135. Abstract.
7. Moran A, Creed T. Changing proton pump inhibitor therapy -Is it safe? Gastroenterology 1999;116(4 pt 2):G1130. Abstract.
8. Hatton BN, Gerson L, Jones W, et al. Assessment of patients at a VA Medical Center treated with omeprazole due to lansoprazole failure. Gastroenterology 1999;116(4 pt 2):A183. Abstract.
9. Krinsky ML, Alexis G, Hirano I. Chronic diarrhea from lansoprazole use in the veteran population. Gastroenterology 1999;116(4 pt 2):A224. Abstract.
10. VA National Acquisition Center. National Contract Information Center. 1998. http://www.va.gov/oa&mn/nac/scripts/pharm/national/Descrip. idc. Accessed January 1, 1999.
11. Department of Veterans Affairs Office of Public Affairs News Service. VA implements national drug formulary [press release]. May 9, 1997.
12. Goff JS. Lansoprazole: A cause for secretory diarrhea. Am J Gastroenterol 1998;93:2298-2299.
13. Mikherjee S. Lansoprazole associated diarrhea. An emerging problem? Abstract presented at: ACG National Fellows' Forum; August 21-24, 1997, Colorado Springs, CO.
14. Thomson RD, Bensen SP, Toor A, Maheshwari Y. Lansoprazole associated with microscopic colitis. Poster presented at: Digestive Disease Week; May 16-22, 1998; New Orleans, LA. Poster #4084.
15. Lansoprazole [package insert]. Deerfield, IL: TAP Pharmaceuticals; June 1999.
16. Damman HG, Von zur Muehlen A, Balks HJ, Damaschke A, Steinhoff J. The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers. Aliment Pharmacol Ther 1993;7:191-196.
17. Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. Ann Intern Med 1996;124:859-867.
18. Avner D, Dorsch ER, Jennings DE, Greski-Rose PA. A comparison of three doses (15, 30, and 60 mg) and placebo in the treatment of duodenal ulcer. Aliment Pharmacol Ther 1995;5:521-528.
19. Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole heals erosive esophagitis resistant to histamine H2-receptor antagonist therapy. Am J Gastroenterol 1997;92:429-437.
20. Earnest DL, Dorsch ER, Jones J, Jennings DE, Greski-Rose PA. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis. Am J Gastroenterol 1998;93:238-243.
21. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? Gastroenterology 1990;99:345-351.
22. Seensalu R, Iwarzon M, Janczewska I, Hammarlund B, Oksanen A. Dose response comparison of lansoprazole and omeprazole on 24-hour gastric acidity and plasma gastrin in healthy volunteers. Gastroenterology 1995;108:A215. Abstract.
23. Schindlbeck NE, Klauser MD, Vorderholzer WA, Muller-Lissner SA. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995;155:1808-1812.
24. Hendel J, Hendel C, Hage B, Aggestrup S, Neilsen OH. Monitoring omeprazole treatment in gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 1996;8:417-420.
25. Lind T, Cederberg C, Ekenved G. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983;24:270-276.
26. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety. Ann Intern Med 1994;121:161-167.
27. Klinkenberg-Knol EC. Eleven years of experience of continuous maintenance treatment with omeprazole. Poster presented at: Digestive Disease Week; May 16-22, 1998; New Orleans, LA. Poster #G0735.
28. Jaspersen D, Dichl KL, Schoeppner H, Geyer P, Martens E. A comparison of omeprazole, lansoprazole, and pantoprazole in the maintenance treatment of severe reflux esophagitis. Aliment Pharmacol Ther 1998;12:49-52.
29. Koop H, Kuly S, Flug M, et al. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Eur J Gastroenterol Hepatol 1996;8:915-918.
30. Blansbard C, Millson C, Sercombe J, Pounder RE. The effects of rabeprazole on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. Gut 1996;39(suppl 3):A47-A48.
31. Cloud M, Enas N, Humphries T, Bassion S. Rabeprazole in treatment of acid peptic diseases: Results of three placebo-controlled, dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998;43:993-1000.
32. Beck IT, Champion MC, Lemire S, et al. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. Can J Gastroenterol 1997;11(suppl B):7B-20B.
33. Moss SF, Arnold R, Tytgat GN, et al. Consensus statement for management of gastroesophageal reflux disease: Result of workshop meeting at Yale University School of Medicine, Department of Surgery, November 16 and 17, 1997. J Clin Gastroenterol 1998;271:6-12.
34. American College of Clinical Pharmacy. Guidelines for therapeutic interchange. Pharmacotherapy 1993;133:252-256.
35. Soumerai SB, Avorn J. Principles of educational outreach ("academic detailing") to improve clinical decision making. JAMA 1990;263:549-556.
36. Nelson WW, Vermuelen LC. Evaluation of clinical and humanistic outcomes in patients with gastroesophageal reflux disease after conversion from omeprazole to lansoprazole. Paper presented at: ASHP Midyear Clinical Meeting; December 6-10, 1998; Las Vegas, NV. Abstract 33Dec:CR-4.